Multiple Myeloma Treatment Recommendations
For newly diagnosed multiple myeloma, transplant-eligible patients should receive quadruplet induction therapy with daratumumab-bortezomib-lenalidomide-dexamethasone (Dara-VRd), followed by autologous stem cell transplantation and maintenance with daratumumab-lenalidomide, while transplant-ineligible patients should receive daratumumab-lenalidomide-dexamethasone (DRd) continued until progression. 1, 2
Initial Assessment and Risk Stratification
Before initiating treatment, all patients require risk stratification using cytogenetics and FISH testing. High-risk features include del(17p), t(4;14), t(14;16), t(14;20), gain 1q, or p53 mutation 3. The presence of two high-risk factors defines "double-hit" myeloma, while three or more constitutes "triple-hit" myeloma—both requiring intensified treatment approaches 3.
Transplant eligibility is determined by age, performance status, and comorbidities rather than a strict age cutoff. Use the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) or Myeloma Comorbidity Index to assess fitness 4.
Transplant-Eligible Patients
Induction Therapy (3-4 cycles before stem cell collection)
Preferred regimen: Daratumumab-bortezomib-lenalidomide-dexamethasone (Dara-VRd) is now the standard of care based on the PERSEUS trial, which demonstrated 84.3% 4-year PFS versus 67.7% with VRd alone 1. This represents a 58% reduction in disease progression risk (HR 0.42, P<0.001).
Alternative for standard-risk patients: Bortezomib-lenalidomide-dexamethasone (VRd) remains acceptable for standard-risk disease, with demonstrated superior PFS and OS compared to lenalidomide-dexamethasone alone 5, 3.
For high-risk patients (especially double/triple-hit): Quadruplet therapy with daratumumab is essential—either Dara-VRd or daratumumab-bortezomib-thalidomide-dexamethasone from the CASSIOPEIA trial (39% vs 26% complete response rate) 6, 1.
Critical considerations:
- Avoid prolonged exposure to alkylating agents (melphalan, nitrosoureas) before stem cell harvest to preserve stem cell reserve 7
- Consider harvesting stem cells before extensive lenalidomide exposure 7
- Administer herpes zoster prophylaxis with proteasome inhibitors 7
- Use subcutaneous bortezomib for patients with pre-existing or high-risk peripheral neuropathy 7
- Provide aspirin or therapeutic anticoagulation with immunomodulatory drugs for thrombosis prophylaxis 7
Autologous Stem Cell Transplantation
Conditioning: Melphalan 200 mg/m² remains the standard preparative regimen 8.
Timing: Proceed to ASCT after 3-4 induction cycles in high-risk patients. Standard-risk patients may collect stem cells and continue induction therapy, delaying ASCT until first relapse without compromising outcomes 5, 3.
Tandem transplant: Consider for high-risk patients not achieving very good partial response after first ASCT 8, 4.
Consolidation
Two cycles of the same induction regimen post-ASCT 1.
Maintenance Therapy
Preferred: Daratumumab-lenalidomide until progression based on AURIGA trial (82.7% vs 66.4% PFS at 30 months with lenalidomide alone) 1.
For standard-risk patients: Lenalidomide alone is acceptable (category 1) 7.
For high-risk patients: Bortezomib-based maintenance or bortezomib plus lenalidomide is essential 9, 3.
Important caveat: Discuss increased risk of secondary malignancies with lenalidomide maintenance, though survival benefits outweigh risks 7.
Transplant-Ineligible Patients
Primary Therapy
Preferred regimen: Daratumumab-lenalidomide-dexamethasone (DRd) continued until progression. The MAIA trial demonstrated 44% reduction in disease progression risk (HR 0.56, P<0.001) with 93% overall response rate versus 81% with lenalidomide-dexamethasone 10, 6.
Alternative for standard-risk patients: VRd for 8-12 cycles followed by lenalidomide maintenance 5, 3.
For elderly/frail patients: Doublet regimens are acceptable when triplets are not tolerated 7. Options include:
- Bortezomib-melphalan-prednisone (VMP) 8
- Melphalan-prednisone-thalidomide (MPT) 8
- Bendamustine-prednisone for patients with pre-existing neuropathy 8
For high-risk patients: Use bortezomib-containing regimens (VRd or VRd lite) rather than DRd 11.
Supportive Care Essentials
Bone disease management:
- Zoledronic acid or pamidronate for 2 years, with extended dosing intervals if disease stable 12
- Denosumab is non-inferior alternative, especially with renal impairment 12
Renal failure: Bortezomib-based regimens are preferred (no dose adjustment needed). Avoid lenalidomide dose reduction when possible; use carfilzomib-cyclophosphamide-dexamethasone as alternative 6, 4.
Infection prophylaxis:
- Herpes zoster prophylaxis mandatory with proteasome inhibitors 7
- Consider pneumocystis prophylaxis with daratumumab-containing regimens
Relapsed/Refractory Disease
After 1-3 Prior Therapies
Preferred regimens:
- Daratumumab-lenalidomide-dexamethasone (category 1) 7
- Daratumumab-bortezomib-dexamethasone (category 1) 7
- Carfilzomib-lenalidomide-dexamethasone (category 1) 7
- Elotuzumab-lenalidomide-dexamethasone (category 1) 7
- Ixazomib-lenalidomide-dexamethasone (category 1) 7
Key principle: Repeat primary induction therapy if relapse occurs >6 months after completion 7.
After ≥2 Prior Therapies (Including IMiD and PI)
Preferred regimens:
- Pomalidomide-bortezomib-dexamethasone 7
- Pomalidomide-dexamethasone (category 1) 7
- Panobinostat-bortezomib-dexamethasone (category 1) 7
Emerging options: T-cell redirecting therapies (CAR-T, bispecific antibodies) for heavily pretreated patients 2, 13.
Monitoring and Response Assessment
Advanced imaging: Use whole-body low-dose CT or FDG-PET/CT for initial workup and follow-up. Use the same modality consistently 10. MRI is acceptable when PET/CT unavailable.
MRD assessment: While MRD negativity correlates with improved PFS/OS, do not modify therapy based solely on MRD status outside clinical trials 5. Exception: consider treatment intensification in young patients with high-risk disease remaining MRD-positive.
Follow-up frequency: Every 3-6 months with serum protein electrophoresis, free light chains, and complete blood count 10.
Common Pitfalls to Avoid
- Do not use melphalan-containing regimens before stem cell collection in transplant candidates
- Do not use high-dose dexamethasone (40 mg weekly is superior to 160 mg weekly with better survival) 9
- Do not delay treatment in symptomatic patients meeting CRAB criteria 8
- Do not treat asymptomatic (smoldering) myeloma outside clinical trials, except high-risk patients may receive daratumumab monotherapy pending regulatory approval 1